ArticleOrphanet journal of rare diseases2026
Mast cell mediators in hereditary angioedema.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acquired Angioedema-A Challenge in Medical Practice: A Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBradykinin-mediated hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) is often hard to differentiate from mast cell (MC) mediated diseases. MCs can be activated by numerous stimuli, leading to the release of various mediators. Recently, crosstalk between MCs and the complement system has been reported. Clinical observations report a higher prevalence of MC-mediated diseases in the HAE-C1INH population than in the general population.
objectiveTo investigate MC activation in HAE-C1INH.
methodsSerum samples from patients during angioedema attack (HAE-A) and during symptom-free period (HAE-SF), as well as from non-angioedema control subjects were examined. Patients and control subjects had no history of allergic disease and normal levels of both nutritional and inhalant specific IgE. Tryptase, chymase, platelet-activating factor (PAF), leukotriene B4 (LTB4), diamine oxidase (DAO), and eosinophil cationic protein (ECP) were measured.
resultsSerum level of chymase was higher in both HAE-C1INH groups than in the control group (p = 0.020 in both comparisons), while no difference was found between the HAE-A and HAE-SF groups. DAO and ECP did not differ from the control group, but their levels increased during angioedema attack compared to the asymptomatic state (p = 0.018 and 0.004, respectively). No difference was found in the levels of the other mediators in any comparison. Chymase levels during the symptom-free period were significantly lower in those patients who had more than 3 HAE attack in the three months following sampling than in those who had less than that (p = 0.012). No other mediators showed a difference between these two groups.
conclusionSignificantly higher chymase levels in HAE-C1INH patients raise the possibility of the activation of a specific subset of MCs in HAE-C1INH patients. Elevation of DAO and ECP levels during HAE attacks indicates the involvement of bradykinin-independent pathways in edema formation during HAE attacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.